licensing

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading pharmaceutical companies in Brazil, for the commercialization of ADL-018 / bOmalizumab, a proposed biosimilar to Xolair®, in Latin America (LATAM). In 2024, IQVIA recorded approximately $5.0 billion in global sales, with approximately $140 million contributed by the LATAM region. Under the terms of the

GCL’s Subsidiary, 4Divinity, Secures Global Publishing Rights for ‘Kingdom Under Fire: The Civil War’

New name, same mission; Atlas introduces a streamlined interface, stronger security, and AtlasVault for secure document exchange and file management. ALPHARETTA, Ga., Sept. 10, 2025 /PRNewswire/ -- Cornerstone Licensing Services today announced the rebranding of its client portal to...

(NYSE:REV) NEW YORK--(BUSINESS WIRE)--Revlon Consumer Products LLC today announced the renewal of its renowned fragrance license agreement with global music superstar and seven-time Grammy winning recording artist, Christina Aguilera. This long-term agreement marks the continuation of a collaboration between Christina Aguilera and Revlon that spans more than ten years. It also coincides with over two decades since the launch of Aguilera’s debut fragrance. Through this renewed deal, Revlon and Aguilera wil

WASHINGTON--(BUSINESS WIRE)--FS Vector, a leading strategic consulting firm for companies that are innovating in financial services, is announcing the launch of its Examinations offering to support companies with all single-state, multistate, investor, and federal financial services exams. FS Vector’s new Examinations offering is driven by the company’s Licensing team, headed by Emily Goodman, Partner, who brings over two decades of experience building and advising in fintech and financial serv

(ZYDUSLIFE) AHMEDABAD, India and NIJMEGEN, Netherlands, Sept. 4, 2025 /PRNewswire/ -- Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into...

NEW YORK--(BUSINESS WIRE)-- #1Money--1Money proudly announced it has secured a comprehensive suite of financial licenses across multiple jurisdictions, including the USA and Bermuda.

(NASDAQ:AVDL) – Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia –

(ATY) VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTCQX: ATCMF) is pleased to announce that the Ministry of the Environment, Water, and Ecological Transition (MAATE) successfully concluded the Community Participation Process for Environmental Consultation (PPC) as a final step in the process prior to granting the Environmental License for exploitation.

ROCHESTER, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Exclusive license broadens Vyriad’s delivery portfolio with a novel viral targeting approach designed to preserve potency, while improving specificity

(NASDAQ:TNFA) NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has entered into a licensing agreement for an innovative processing accelerator designed to expedite compute-intensive computations In partnership with LightSolver Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovation. TNF holds exclusive rights to the use of its computing technology in cryptocurrency and blockchain app

(RHHBY) The Agreement Closes the Litigation Between the Parties BOULDER, Colo., Aug. 29, 2025 /PRNewswire/ -- Foresight Diagnostics ("Foresight") today announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche")...

TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- G2 Goldfields Inc. (“G2” or the “Company”) (TSX: GTWO; OTCQX: GUYGF) is pleased to announce that the Ministry of Natural Resources and Guyana Geology and Mines Commission have approved the issuance of two Large Scale Prospecting Licenses (“PL’s”) which encompass the Company’s high-grade Oko-Ghanie Gold Deposit (“Oko” or the “Project”) in Guyana.

Increasing Leqembi® royalties and new partnership with Novartis STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- Events during the second quarter 2025 The European Commission granted Marketing Authorisation (MA) for Leqembi® (lecanemab), triggering a milestone payment of EUR 20 M from Eisai The...

TAMPA, Fla., Aug. 27, 2025 /PRNewswire/ -- Home Frosting, a Tampa-based interior design firm and HF Pillow and Book Bar, announces its license agreement with America250™, the bipartisan organization charged by Congress to lead celebrations for the 250th anniversary of the signing of the...

Miata Metals Announces Exploitation License Renewal for the Sela Creek Gold Project

BELIZE CITY, Belize, Aug. 21, 2025 /PRNewswire/ -- Global iGaming brand BC.GAME has announced that its local entity, Blockdance Africa Limited, has been granted both a Public Gaming Licence and a Bookmakers Off-the-Course Licence by the Betting Control and Licensing Board (BCLB) of Kenya....

DURHAM, N.C.--(BUSINESS WIRE)--BioSkryb announced the execution of an exclusive license to a patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco.

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential...

BURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies. The licensing of vantictumab represents a strategic expansion of āshibio’s p